Results 81 to 90 of about 1,343,260 (212)

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Orexin A ameliorates HBV X protein-induced cytotoxicity and inflammatory response in human hepatocytes

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Hepatitis B virus is one of the main causes of hepatitis and hepatocellular carcinoma (HCC). Hepatitis B virus-encoded X protein (HBx) has been shown to be involved in many aspects of the pathogenicity of liver diseases.
Li Wang   +4 more
doaj   +1 more source

Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Lemborexant 10 mg, a dual orexin‐receptor antagonist (DORA), did not elicit respiratory depressant effects, as measured by peripheral oxygen saturation (SpO2) or apnea–hypopnea index (AHI), in subjects with moderate‐to‐severe chronic obstructive pulmonary disease (COPD).
Jocelyn Y. Cheng   +3 more
wiley   +1 more source

Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton

open access: yesJournal of Sleep Research, EarlyView.
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein   +10 more
wiley   +1 more source

Differential roles of orexin receptors in the regulation of sleep/wakefulness

open access: yesFrontiers in Endocrinology, 2013
Orexin A and orexin B are hypothalamic neuropeptides that play critical roles in the regulation of sleep/wakefulness, as well as in a variety of physiological functions such as emotion, reward, and energy homeostasis.
Michihiro eMieda   +2 more
doaj   +1 more source

Immunohistochemical identification and localization of orexin A and orexin type 2 receptor in the horse gastrointestinal tract

open access: yes, 2009
The aim of the present study was to investigate the presence and the distribution of cells containing orexin A and orexin type 2 receptor in the horse stomach and gut, by means of immunohistochemical techniques.
PASCUCCI, Luisa   +5 more
core   +1 more source

Daridorexant‐ Case Report of Possible Side‐Effect in Rare Mitochondrial Disorder

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT This case report describes a 40‐year‐old woman with maternally inherited diabetes and deafness (MIDD), a rare mitochondrial disorder, who received treatment with daridorexant due to severe chronic insomnia. She developed progression of her MIDD symptoms during treatment.
Sven Svedmyr, Joel Bergqvist
wiley   +1 more source

The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. [PDF]

open access: yes, 2012
Recent studies have implicated the hypocretin/orexinergic system in reward-seeking behavior. Almorexant, a dual orexin/hypocretin R(1) and R(2) receptor antagonist, has proven effective in preclinical studies in promoting sleep in animal models and was ...
Steven P Lieske   +31 more
core   +2 more sources

Real‐World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 4, December 2026.
Using real‐world data, AAP augmentation patterns were evaluated in patients with MDD initially treated with antidepressant monotherapy. AAP augmentation therapy was initiated after a relatively long interval. Although only a small proportion of patients received this therapy, nearly half showed claims‐defined continuation for more than 6 months ...
Hikaru Hori   +8 more
wiley   +1 more source

UK Medical Cannabis Registry: A Two‐Year Prospective Observational Cohort Study of Clinical Outcomes in Insomnia

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 4, December 2026.
Insomnia affects around one in ten adults. In this 2‐year UK Medical Cannabis Registry cohort study of 211 adults with insomnia, treatment with cannabis‐based medicinal products was associated with a sustained improvement in self‐reported sleep quality across 24 months.
Aran Koye   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy